Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS

Approximately 30% of human cancers harbor a gain‐in‐function mutation in the RAS gene, resulting in constitutive activation of the RAS protein to stimulate downstream signaling, including the RAS‐mitogen activated protein kinase pathway that drives cancer cells to proliferate and metastasize. RAS‐dr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MedComm (2020)
Main Authors: Ward, Antonio B., Keeton, Adam B., Chen, Xi, Mattox, Tyler E., Coley, Alex B., Maxuitenko, Yulia Y., Buchsbaum, Donald J., Randall, Troy D., Zhou, Gang, Piazza, Gary A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7567124/
https://ncbi.nlm.nih.gov/pubmed/33073260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mco2.10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados